Everand Logo

Welcome to Everand!

  • STAT

    AIDS activists urge N.Y. attorney general to probe Gilead for antitrust violations

    The activists are concerned Gilead may have reached agreements that allow it to improperly forestall competition to its Truvada HIV prevention pill.
    by Ed Silverman Aug 29, 2017 3 minutes

    A group of prominent AIDS activists is urging the New York attorney general to investigate Gilead Sciences (GILD) for potential antitrust violations in connection with deals the drug maker struck with rivals that sought to sell generic versions of a best-selling HIV treatment.

    The activists are concerned Gilead may have reached agreements with the companies that allow it to improperly forestall competition to its Truvada HIV prevention pill, according to an Aug. 4 they wrote to Eric Schneiderman, the New York attorney general. Those deals were reached three years ago to settle patent litigation and generic

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks